New vaccine combo aims to boost cancer fight in lung and esophageal patients

NCT ID NCT04908111

First seen Apr 14, 2026 · Last updated Jun 09, 2026 · Updated 10 times

Summary

This early-phase trial tests two experimental vaccines (ChAdOx1 and MVA) designed to help the immune system target cancer proteins MAGE-A3 and NY-ESO-1. About 15 adults with advanced non-small cell lung cancer or squamous esophageal cancer will receive the vaccines alongside their usual chemotherapy and an immune checkpoint inhibitor. The main goal is to check safety and tolerability, with a secondary focus on how long the disease stays under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • Blackpool Victoria Hospital

    Blackpool, United Kingdom

  • Churchill Hospital

    Oxford, United Kingdom

  • Guy's and St Thomas' NHS Foundation Trust

    London, United Kingdom

  • Leicester Royal Infirmary

    Leicester, United Kingdom

  • Royal Preston Hospital

    Preston, United Kingdom

  • Southampton General Hospital

    Southampton, United Kingdom

  • St James's University Hospital

    Leeds, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

Conditions

Explore the condition pages connected to this study.